Hepatocyte FH

Ready to order?
UK +44 (0)1223 497106
USA 617-674-3260

DefiniGEN provide disease modelled familial hypercholesterolemia hepatocytes which are highly functional CRISPR gene-edited human hepatocytes. Familial hypercholesterolemia (FH) is an autosomal disorder of lipoprotein metabolism caused mainly by mutations in the low-density lipoprotein receptor (LDLR) gene. These cells can offer disease modelling and drug discovery researchers unprecedented tool for elucidating the underlying mechanisms of this disease.


Production of Familial Hypercholesterolemia disease modelled hepatocytes using CRISPR technology

Figure 1. For the production of Def-HEP FH cells, fibroblasts are first reprogrammed into iPSC using the Nobel Prize winning technology developed by Yamanaka and colleagues. Horizon CRISPR gene-editing is then used to introduce a precise genetic mutation into the LDLR gene of an iPS cell line. Def-HEP FH hepatocytes represent an optimized disease model for drug discovery applications and a principal tool for elucidating the underlying mechanisms of the disease.

Horizon Logo

  • Highly standardized cell product containing >98% human hepatocyte cells with consistent performance and biologically relevant data
  • Disease circuit verified mutation in the LDLR gene E101K results in significantly impaired LDL uptake in the cells

Genetic Validation and Cell Viability

Def-HEP FH cells have been validated and verified for the E101K genetic mutation in the LDLR gene. Typical viabilities of the thawed hepatocytes are >70% upon receipt.

Disease circuit verification

Sequence confirmation of LDLR E101K mutation in hepatocyte FH cells

Figure 2. Sequence confirmation of LDLR E101K mutation in Def-HEP FH cells.

Functional Test

The in vivo functional implications of LDL receptor deficiency are conserved in our model, as shown by immunostaining and FACS analysis demonstrating that Def-HEP FH iPSC hepatocytes have an impaired ability to incorporate LDL receptor-specific binding of Dil-LDL is followed by internalization of the bound complex and lysosomal hydrolysis of the ligand. Increase in the fluorescence intensity per cell is hence used as a measure of Dil-LDL uptake and, implicitly, as an indication of LDL-R presence. These results demonstrate that CRISPR generated disease-specific human iPSC can successfully be used to model FH.

Uptake of LDL is impaired in LDLR mutated hepatocytes (FH) when compared to wild-type controls.

Figure 3. These microscopy images demonstrate that uptake of LDL was impaired in the LDLR mutation line in comparison to WT control.


Graph depicting decreased Dil-LDL internalization by LDLR mutated hepatocytes (FH) in comparison to wild-type controls

Figure 4. Quantitative LDL receptor assays based on fluorescence Dil-LDL internalization have demonstrated that Def-HEP FH iPSC-derived hepatocytes have a significantly impaired ability to incorporate LDL relative to the isogenic control Def-HEP WT over a range of LDL substrate ranges.

We recommend that you use our online system to identify the products of interest and their respective product codes. To order we will require the following information:

Product code(s) of the item(s) you wish to order (e.g. Def-HEP FH)
Your name, email address, title and organization
Shipping address and billing address with contact names
Purchase Order number if you have one
Telephone number

For further information please contact us: